Novartis AG (NVS) Fair Value 2026

NVS · Pharmaceutical Preparations ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

2.6 /10

32 fundamental signals · 13 models active

Value Trap Risk

(—/100)

Quick Summary — As of 2026-07-15, Novartis AG (NVS) trades at $150.78, approximately 177% above CirclFi’s Bayesian DCF fair value of $54.50. QOC: 2.6/10. 13/13 models active.

Key Facts

Ticker
NVS
Price
$150.78
Quality Score
2.6/10
Value Trap Risk
—/100
Models Active
13/13
Last Updated
Strength: First Chicago suggests +47.8% upside with 35% confidence
Risk: Below-average Quality Score of 2.6/10 signals weak fundamentals

Is Novartis AG (NVS) Undervalued or Overvalued in 2026?

According to CirclFi’s 13-model valuation engine, Novartis AG (NVS) appears overvalued as of : the median of 13 independent fair value estimates is $107.24, 28.9% below the current price of $150.78. Estimates range from $10.09 to $222.81. NVS scores 2.6/10 on fundamental quality and —/100 on value-trap risk.

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Novartis AG Stock in 2026? →

Valuation Matrix

13 Intrinsic Value Models vs. Current Price ($150.78)

Core Models (Unlocked)
Model Fair Value Upside
Bayesian DCF
Low Conviction
$54.50 -63.9%
Earnings Power Value
High Conviction
$96.94 -35.7%
CUCE Ensemble
Low Conviction
$107.24 -28.9%
First Chicago
Medium Conviction
$222.81 +47.8%

Unlock the Full Matrix

Access 9 additional models including EROIC Spread, Markov DDM, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 13 Models →

Cancel anytime · No contracts · Instant access

What Is Novartis AG (NVS) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, the balance of valuation evidence tilts cautious on Novartis AG at its current price of $150.78. The composite intrinsic value is estimated at $117.21 (-22.3% average return), with 9 models flagging overvaluation risk. Notably, First Chicago sees the most upside at +47.8% (fair value: $222.81), while Dynamic NAV is the most conservative at -93.3% ($10.09). The spread between these extremes — +141.1% — reveals how different analytical frameworks can reach starkly different conclusions.

What Do the Models Say About NVS?

13 of 13 models are currently active for NVS. Of these, 4 models suggest upside while 9 models suggest overvaluation. The Bayesian DCF estimates NVS's intrinsic value at $54.50, implying -63.9% downside from the current price. See which stocks rank higher →

How Does NVS Rank in Pharmaceutical Preparations?

Among 431 Pharmaceutical Preparations stocks, NVS ranks #392 by Quality of Company score. CirclFi's QOC score of 2.6/10 evaluates 32 fundamental signals. A score of 2.6 signals below-average fundamentals.

See all Most Undervalued Pharmaceutical Preparations Stocks →

Within the Pharmaceutical Preparations space, Novartis AG competes in an environment where revenue per drug often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.

Is NVS a Value Trap?

The Value Trap algorithm is not active for NVS. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

13 of 13 models are active for Novartis AG. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Novartis AG's fundamental quality profile registers 2.6/10. This concerning score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

The gap between the most bullish and bearish model spans +141.1% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every NVS valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across NVS's 13 active models, average confidence is 26%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Novartis AG Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Pharmaceutical Preparations Stocks Should You Also Analyze?

8 related Pharmaceutical Preparations stocks with 13-model coverage

Read investment analysis: AZN · CPRX · HRMY · NVO · SIGA

See all Pharmaceutical Preparations stocks ranked →

Frequently Asked Questions About Novartis AG

What is Novartis AG's intrinsic value in 2026?

Based on CirclFi's 13-model analysis, Novartis AG (NVS) has multiple fair value estimates. The Bayesian DCF model runs 10,000 Monte Carlo simulations with jump-diffusion to estimate intrinsic value at $54.50. The Quality of Company score is 2.6/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is NVS overvalued or undervalued right now?

At $150.78, 4 of 13 active models suggest NVS may be undervalued, while 9 indicate potential overvaluation. The median of all 13 fair value estimates is $107.24, 28.9% below the current price of $150.78 — a consensus view that NVS is overvalued. The assessment depends on which methodology best fits Novartis AG's business model in Pharmaceutical Preparations.

What does a Quality of Company score of 2.6 mean for NVS?

Novartis AG's QOC of 2.6/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on NVS?

CirclFi analyzes NVS with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 13 of 13 are active for this stock. Read the full methodology →

Is NVS a value trap in 2026?

CirclFi's Value Trap algorithm does not have sufficient data for NVS at this time. Browse stocks by value-trap risk →

Cite this analysis — “According to CirclFi’s 13-model valuation engine, Novartis AG (NVS) has a median fair value of $107.24 — 28.9% below the current price of $150.78 — as of 2026-07-15.” Source: circlfi.com/stock/NVS/ · Methodology

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 13 mathematical frameworks give you clarity on NVS.

Unlock All 13 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access